Would you offer anti-HER2 therapy to a patient found to have heterogenous HER2+ residual disease after original treatment for TNBC using the KEYNOTE-522 regimen?

This is complicated and there isn't a data driven right/wrong answer for this type of situation that I am aware of. Neoadjuvant treatment can cause shifts in biomarker results in residual tumor tissue compared to the pre-treatment specimen. KY-522 didn't do re-testing of residual tumor. I am not routinely in the habit of re-testing residual disease after neoadjuvant therapy for TNBC except for lack of response. I have seen this question pop up too after HER2 directed therapy usually in the context of giving TDM1 or not when the HER2 status has changed. In KATHERINE, they were eligible based on the pre-treatment testing result, not post-treatment. Additional information would be important like how much residual disease was there (RCB status?...